English Patent Granted for Allosteric Site Prediction Technology for Undruggable Proteins
— Expanding the range of druggable targets through computational drug discovery powered by the quantum-inspired optimiza...
English
English English The “β2GPI Neoself Antibody Test,” a Novel Test for RPL and RIF, Now Launched in Malaysia
July 9th, 2025AOI Biosciences Inc. AOI Biosciences Inc. (Headquarters: Ibaraki, Osaka; CEO: Shinichi Sueta; hereinafter ...
English AOI Biosciences and Sumitomo Corporation Launches β2GPI Neo-Self Antibody Test in Indonesia
~ Joint Research Agreement Signed with Hermina Group ~
June 24, 2025AOI Biosciences Inc. AOI Biosciences Inc. (Headquarters: Ibaraki, Osaka, Japan; CEO: Shinichi Sueta; herein...
English β2GPI Neoself Antibody Test Recognized as Advanced Medical Care by the Japanese Ministry of Health, Labour and Welfare
AOI Biosciences Inc. (Headquarters: Ibaraki, Osaka; CEO: Shinichi Sueta; hereinafter referred to as "AOI Bio.") today an...